Working… Menu

Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04843774
Recruitment Status : Recruiting
First Posted : April 14, 2021
Last Update Posted : May 12, 2021
Information provided by (Responsible Party):
NYU Langone Health

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : October 14, 2022